JP6506752B2 - Apiミグリトールのための超速崩壊錠剤処方 - Google Patents
Apiミグリトールのための超速崩壊錠剤処方 Download PDFInfo
- Publication number
- JP6506752B2 JP6506752B2 JP2016526560A JP2016526560A JP6506752B2 JP 6506752 B2 JP6506752 B2 JP 6506752B2 JP 2016526560 A JP2016526560 A JP 2016526560A JP 2016526560 A JP2016526560 A JP 2016526560A JP 6506752 B2 JP6506752 B2 JP 6506752B2
- Authority
- JP
- Japan
- Prior art keywords
- tablet
- miglitol
- mixture
- tableting
- particle size
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Claims (6)
- 20%〜30%のミグリトールと、65%〜78%のトウモロコシデンプン、三ケイ酸マグネシウムおよび架橋ポリビニルピロリドンである不溶性成分を含み、更に打錠補助剤を含有していてもよい錠剤であって、
ミグリトールが15〜30μmの平均粒子径を有する結晶の凝集形態で存在し、該凝集物が400μmを超える粒子サイズを有する前記錠剤。 - 25%〜28%のミグリトールと、68%〜75%のトウモロコシデンプン、三ケイ酸マグネシウムおよび架橋ポリビニルピロリドンである不溶性成分を含有する、請求項1に記載の錠剤。
- 100秒未満の崩壊時間を有する、請求項1または2に記載の錠剤。
- 成分を混合すること、および、
さらなる媒介物なしに該混合物を圧縮により打錠すること
を含む、請求項1〜3のいずれか一項に記載の錠剤の製造方法。 - 成分を混合すること、
該混合物を初期圧縮にかけること、および
それを圧縮により打錠すること
を含む、請求項1〜3のいずれか一項に記載の錠剤の製造方法。 - すぐ打錠できる混合物を含む容器と打錠機フィーダーとの間の連結部として、可撓性金属箔チューブが使用される打錠機を用いる、請求項1〜3のいずれか一項に記載の錠剤成形方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013150272 | 2013-07-19 | ||
JP2013150272 | 2013-07-19 | ||
PCT/EP2014/065016 WO2015007676A1 (en) | 2013-07-19 | 2014-07-14 | Super quick disintegrating tablet formula for api miglitol |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016533383A JP2016533383A (ja) | 2016-10-27 |
JP6506752B2 true JP6506752B2 (ja) | 2019-04-24 |
Family
ID=51176393
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016526560A Active JP6506752B2 (ja) | 2013-07-19 | 2014-07-14 | Apiミグリトールのための超速崩壊錠剤処方 |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP3021837A1 (ja) |
JP (1) | JP6506752B2 (ja) |
CN (1) | CN105377241A (ja) |
HK (1) | HK1221915A1 (ja) |
WO (1) | WO2015007676A1 (ja) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1615862A (zh) * | 2003-11-10 | 2005-05-18 | 浙江医药股份有限公司新昌制药厂 | 一种治疗ⅱ型糖尿病的米格列醇口腔崩解片及其制备方法 |
JP5291324B2 (ja) | 2007-11-01 | 2013-09-18 | 沢井製薬株式会社 | 口腔内崩壊錠 |
RU2010128019A (ru) * | 2007-12-08 | 2012-01-20 | Байер Шеринг Фарма Акциенгезельшафт (DE) | Пероральная диспергируемая таблетка |
JP2009196940A (ja) * | 2008-02-22 | 2009-09-03 | Takada Seiyaku Kk | 口腔内速崩壊錠及びその製造法 |
CN102600149B (zh) * | 2012-02-02 | 2013-12-04 | 西藏易明西雅生物医药科技有限公司 | 一种治疗糖尿病的药物组合物 |
WO2015008825A1 (ja) * | 2013-07-19 | 2015-01-22 | 株式会社三和化学研究所 | 口腔内崩壊錠 |
-
2014
- 2014-07-14 JP JP2016526560A patent/JP6506752B2/ja active Active
- 2014-07-14 WO PCT/EP2014/065016 patent/WO2015007676A1/en active Application Filing
- 2014-07-14 CN CN201480040954.3A patent/CN105377241A/zh active Pending
- 2014-07-14 EP EP14738534.8A patent/EP3021837A1/en not_active Withdrawn
-
2016
- 2016-08-29 HK HK16110220.3A patent/HK1221915A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
EP3021837A1 (en) | 2016-05-25 |
WO2015007676A1 (en) | 2015-01-22 |
JP2016533383A (ja) | 2016-10-27 |
HK1221915A1 (zh) | 2017-06-16 |
CN105377241A (zh) | 2016-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1276466B1 (en) | Directly compressed solid dosage particles | |
JP2009525316A5 (ja) | ||
JP5753081B2 (ja) | 口腔内崩壊性マンニトール | |
KR20130041144A (ko) | 데페라시록스의 경구투여용 제제 | |
TW201124157A (en) | Microcrystalline cellulose and calcium phosphate compositions useful as pharmaceutical excipients | |
JP2011246428A (ja) | 口腔内崩壊型医薬品及びその製造方法 | |
CN105555261A (zh) | 包含交聚维酮的片剂 | |
JP6506752B2 (ja) | Apiミグリトールのための超速崩壊錠剤処方 | |
CA2747345C (en) | Precompacted fast-disintegrating formulations of compounds with a low oral bioavailability | |
GB2536519A (en) | Method of preparing an extruded composition | |
AU2016217658B2 (en) | Method of producing a granulated composition | |
JP5755382B2 (ja) | 口腔内崩壊錠 | |
CN105555316B (zh) | 通过二阶段的湿式制粒工序制备的崩解性颗粒组合物及含有该组合物的口腔内崩解片剂 | |
JPWO2017170763A1 (ja) | 崩壊錠及びその製造方法 | |
JP2022076474A (ja) | リバーロキサバン含有口腔内崩壊錠 | |
EP2575755A2 (en) | Orodispersible tablets of erythritol and isomalt | |
JP2009249377A (ja) | 水懸濁性を向上させた細粒剤 | |
JP5160156B2 (ja) | 栄養機能食品錠剤 | |
Jaiswar et al. | Hot melt extrusion: continuous process of preparation of sustained released matrix tablet by using hydroxypropylcellulose | |
JP6004882B2 (ja) | 圧縮成形に用いるためのマンニトール賦形剤及びこれを含有する錠剤 | |
JP6451310B2 (ja) | 固形医薬組成物及びその製造方法 | |
JP2006022060A (ja) | 制酸・緩下用水分散液およびそのための錠剤 | |
JP6807270B2 (ja) | エリスリトールと多孔性無機物の複合体粒子及びそれを含む錠剤 | |
EP2238972A2 (de) | Zusammensetzung umfassend einen hydrophoben Wirkstoff sowie ein Phospholipid | |
JP2005247693A (ja) | ビタミンb1誘導体組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170710 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180515 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180809 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181114 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190312 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190329 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6506752 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |